Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05192538
Other study ID # RE-Endoloop
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 10, 2022
Est. completion date May 1, 2022

Study information

Verified date March 2022
Source Affiliated Hospital to Academy of Military Medical Sciences
Contact Yan Liu
Phone 13911798288
Email 13911798288@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to evaluate the safety and efficacy of endoscopic endoloop pre-test for gastroesophageal reflux before anti-reflux surgery or endoscopic treatment. In the study, the investigators used the novel pre-test to narrow the gastric cardia to control symptoms temporarily to decide whether to undergo irreversible surgery or endoscopic treatment.Thirty patients were enrolled and underwent endoscopic endoloop pre-test treatment. The Primary outcome in this study was measured by the percent reduction in post-procedure GERD symptoms as evidenced by analysis of the GERD-HRQL (Health Related Quality of Life) questionnaire. The secondary outcomes included improvement in esophageal 24-hr pH monitoring, improvement in quality of life questionnaires and safety. Patient follow-up assessments were completed at 7 and 14 days post treatment.


Description:

Gastroesophageal reflux disease (GERD) is a neuromuscular disorder with abnormal reflux of gastric contents into the esophagus.The most common symptoms are heartburn, dysphagia, and regurgitation.Due to less invasion, several endoscopic treatments of GERD have been investigated, such as collagen or radio frequency delivery, and antireflux mucosectomy(ARMS).The disadvantages of these treatment included short-term effectiveness, increasing reflux and ulcer, and serious complications. A novel endoscopic endoloop pre-test treatment has been developed, offering a minimally reversible endoscopic treatment to predict whether the symptoms can be alleviated in order to ultimately decide whether to undergo irreversible surgery or endoscopic treatment, which can be performed in an outpatient setting.The aim of this study was to assess the feasibility and safety of the pre-test treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date May 1, 2022
Est. primary completion date April 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patients with typical symptoms of GERD with symptomatic response to PPI therapy for = 3 months - Patients considered for non-medical therapy, i.e. unwillingness to take life-long medication in medically-responding disease, suffering from medication side-effects or medically-intractable disease - Pathological esophageal acid exposure after discontinuation of medical therapy, proven by ambulatory 24-hour pH-monitoring with > 5% of time a pH < 4 and a symptom-association probability > 95% - written informed consent Exclusion Criteria: - 24 hr acid exposure study showing abnormal esophageal acid exposure <4% - DeMeester Score <14.7 - hiatal hernia (> 3 cm in length) - history of antireflux or esophageal/gastric surgery - severe psychiatric disease - Barrett's esophagus with dysplasia - esophageal stenosis/malignancy - pregnancy or lactation - history of low therapeutic compliance - other severe comorbidity (including cardiopulmonary disease, portal hypertension, collagen diseases, morbid obesity, coagulation disorder) - use of anticoagulant or immunosuppressive drugs

Study Design


Intervention

Device:
Endoscopic endoloop pre-test treatment
A novel endoloop was inserted into the gastric cardia by forceps through the single-channel endoscopy. After adjustment of the endoloop's location and angle, it was anchored onto the edge of the gastric cardia with clip and another 1 or 2 clips were inserted to hold the opposite side of endoloop at about 1/2 circumference. Then the hook was connected with the endoloop, which was tighted by slight pulling together of all the clips.

Locations

Country Name City State
China The Fifth Medical Center of Chinese PLA General Hospital Beijing Beijing

Sponsors (3)

Lead Sponsor Collaborator
Affiliated Hospital to Academy of Military Medical Sciences Beijing 302 Hospital, Beijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in GERD-Health Related Quality of Life (HRQL) questionnaire scores GERD-HRQL is a validate questionnaire to evaluate GERD-related esophageal symptoms. The scale range is (0-50); the higher values represents worse outcomes. 3 days
Primary Improvement in GERD-Health Related Quality of Life (HRQL) questionnaire scores GERD-HRQL is a validate questionnaire to evaluate GERD-related esophageal symptoms. The scale range is (0-50); the higher values represents worse outcomes. 7 days
Primary Improvement in GERD-Health Related Quality of Life (HRQL) questionnaire scores GERD-HRQL is a validate questionnaire to evaluate GERD-related esophageal symptoms. The scale range is (0-50); the higher values represents worse outcomes. 14 days
Primary Improvement in GERD-Health Related Quality of Life (HRQL) questionnaire scores GERD-HRQL is a validate questionnaire to evaluate GERD-related esophageal symptoms. The scale range is (0-50); the higher values represents worse outcomes. 21 days
Primary Improvement in GERD-Health Related Quality of Life (HRQL) questionnaire scores GERD-HRQL is a validate questionnaire to evaluate GERD-related esophageal symptoms. The scale range is (0-50); the higher values represents worse outcomes. 1 month
Primary Improvement in Reflux Symptom Index (RSI) questionnaire scores RSI is a validate questionnaire to evaluate GERD-related extra- esophageal symptoms. The scale range is (0-45); the higher values represents worse outcomes. 3 days
Primary Improvement in Reflux Symptom Index (RSI) questionnaire scores RSI is a validate questionnaire to evaluate GERD-related extra- esophageal symptoms. The scale range is (0-45); the higher values represents worse outcomes. 7 days
Primary Improvement in Reflux Symptom Index (RSI) questionnaire scores RSI is a validate questionnaire to evaluate GERD-related extra- esophageal symptoms. The scale range is (0-45); the higher values represents worse outcomes. 14 days
Primary Improvement in Reflux Symptom Index (RSI) questionnaire scores RSI is a validate questionnaire to evaluate GERD-related extra- esophageal symptoms. The scale range is (0-45); the higher values represents worse outcomes. 21 days
Primary Improvement in Reflux Symptom Index (RSI) questionnaire scores RSI is a validate questionnaire to evaluate GERD-related extra- esophageal symptoms. The scale range is (0-45); the higher values represents worse outcomes. 1 month
Secondary Effect on 24-hours esophageal pH-impedance Parameter detected by 24hours esophagel pH-metry. pH-metric and impedance parameters are indicators of procedure effectiveness as able to quantify the presence of gastro-esophageal reflux. 7 days
Secondary Effect on 24-hours esophageal pH-impedance Parameter detected by 24hours esophagel pH-metry. pH-metric and impedance parameters are indicators of procedure effectiveness as able to quantify the presence of gastro-esophageal reflux. 14 days
Secondary Changes in DeMeester score DeMeester score is a composite score which examined six variables (number of reflux episodes, number of episodes longer than 5 minutes, longest reflux duration, total percentage of monitoring time with pH below 4, and the percentage of time with pH below 4 in an upright position and supine position). A score of >14.72 shows a pathological reflux. Higher values represent worse outcomes. 7 days
Secondary Changes in DeMeester score DeMeester score is a composite score which examined six variables (number of reflux episodes, number of episodes longer than 5 minutes, longest reflux duration, total percentage of monitoring time with pH below 4, and the percentage of time with pH below 4 in an upright position and supine position). A score of >14.72 shows a pathological reflux. Higher values represent worse outcomes. 14 days
Secondary Safety and Tolerability of the procedure Incidence of Treatment-Emergent Adverse Events 7 days
Secondary Safety and Tolerability of the procedure Incidence of Treatment-Emergent Adverse Events 14 days
Secondary Safety and Tolerability of the procedure Incidence of Treatment-Emergent Adverse Events 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT06084572 - Prospective Evaluation of pH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus
Completed NCT03568825 - Response Surface Pathway Design With Two Interventional- and One Response Variable in Estimating Minimum Efficacy Dose N/A
Recruiting NCT04703374 - A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects Phase 1
Completed NCT04120025 - Effectiveness of Diaphragmatic Breathing on Reflux Symptoms in Outpatients N/A
Withdrawn NCT04771247 - Endoscopic Cardiac Band Ligation for the Management of Refractory GERD After Laparoscopic Sleeve Gastrectomy N/A
Completed NCT02575287 - Minimal Injuries From Esophagus Detected by Optical Enhancement Systemâ„¢ Associated to Optical Magnification HD Scopes N/A
Completed NCT01710800 - Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy N/A
Completed NCT00287339 - The Utility of Nexium in Chronic Cough and Reflux Disease Phase 4
Completed NCT00287391 - Sleep Disorders and Gastroesophageal Reflux Disease (GERD) Phase 4
Completed NCT00629564 - An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Phase 4
Completed NCT04243668 - ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA) N/A
Completed NCT03558477 - PK/PD Clinical Trial of YYD601 in Healthy Adult Male Phase 1
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Completed NCT05069493 - Long-term Follow-up After Hiatal Hernia Repair by Tension-free Mesh Closure or Simple Suturing
Completed NCT03238534 - Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS Phase 4
Recruiting NCT05974722 - Mesh Vs Pledgets for Repair of Paraesophageal Hernia N/A
Recruiting NCT05781347 - Stretta Versus Conservative Treatment in Obese and Non-obese N/A
Completed NCT06141577 - A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects Phase 1
Recruiting NCT05108038 - A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects Phase 1
Recruiting NCT02587910 - Melanole, a Dietary Supplement, for the Treatment of Gastroesophageal Reflux Disease Phase 2/Phase 3